Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, and Burcelin R
With increased awareness among physicians and patients, especially in recognizing obesity as a disease, it is expected to result in an increase in prescriptions of obesity drugs, the most effective being GLP-1 receptor agonists
Additionally, tirzepatide demonstrates bias at the GLP1R, favoring the synthesis of cAMP over the recruitment of -arrestin [1]
They question whether the manufacturers were aware of these risks and if they adequately informed patients and doctors
Life-Changing Fat Loss Made Easy with Personalized Care, a GLP-1 Medication and Your HSA Now you can use your health benefits to transform your body and health with MyStart